Trial Profile
A Phase I/II Study to Evaluate the Safety and PK of iv Trappsol Cyclo (HP-β-CD) in Patients With Niemann-Pick Disease Type C NPC-1 and the Pharmacodynamic Effects of Treatment Upon Markers of Cholesterol Metabolism and Clinical Outcomes
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Hydroxypropyl betadex (Primary)
- Indications Niemann-Pick disease type C
- Focus Biomarker; Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Cyclo Therapeutics
- 29 Jun 2023 According to a Cyclo Therapeutics media release, data from this study were published in official journal of Molecular Genetics and Metabolism.
- 29 Jun 2023 Results published in a Cyclo Therapeutics Media Release.
- 16 Aug 2022 According to a Cyclo Therapeutics media release, data from this study were presented at the 2022 NPC Patient and Family Conference hosted by the Australian NPC Disease Foundation.